导读： 近期，关税战愈演愈烈，在此背景下，我们特别盘点美国十家科学仪器企业在华的发展布局，以期洞察未来趋势。 他还着重表示，珀金埃尔默太仓工厂扩建项目已完成，新的现代化生产设施和运营平台将在现有的太仓基地附近投产，面积扩大近四倍，并将 逐步实现全品类产线转移。这将进一步提升公司在中国市场的生产和运营规模，更好地服务中国客户。珀金埃尔默将持续关注中国市场与客户 需求的变化，不断推出适应中国市场的产品和解决方案，为中国客户提供创新技术和专业服务。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 2 0 2 5年2月2 8日，胡润研究院发布《2 0 2 4在中国的美国企业特别报告》，报告共收集了7 0家标普5 0 0成分股美国企业的数据，这些企业均披露 了其在中国市场的营收数据。 样本企业在全球市场的收入总额超过2 . 5万亿美元，相当于美国2 0 2 3年GDP总和的9%。报告中不仅提及了苹 果、特斯拉、沃尔玛等知名企业，还特别关注了珀金埃尔默、r e v v it y等科学仪器领域的美国品牌。 回顾历史，自上世纪8 0年代前后，珀金埃 ...

特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 您是否正为实验室搬迁中的设备打包运输、顺序安排而感到压力重？在构建安全管理体系与合规建设时又是否感到困惑？别担心，这场线上会 议将为您送上及时的解决方案！ 本次会议专注于实验室搬迁、安全管理与建设领域，汇聚众多行业专家，带来最前沿的理念和丰富的实践经验，旨在帮助您解决日常工作中所 面临的实际难题。不论您是来自科研机构、高校，还是企业实验室，这里都有您需要的核心内容。 安捷伦Cr o ssLa b服务将在会议中展示，如何为各类实验室的整体搬迁打造定制化的综合方案。我们的搬迁流程涵盖了从搬迁前文件体系确认、 新址规划，到物理搬迁、新实验室的安装调试、验证和网络版软件的验证等各个环节。特别针对GMP实验室，我们还提供定制化的专属增值服 务，确保搬迁全程的合规与高效，助力您的实验室平稳过渡，顺利开启新的篇章。 会议内容要点： 实验室搬迁中的挑战与应对策略 行业内专家分享实战经验 实验室搬迁的成功案例解析 Q&A环节 现场解答与会者的疑问，互动交流，分享更多经验 通过本次会议，我们希望能为您在实 ...

Core Insights - Smackover Lithium, a joint venture between Standard Lithium and Equinor, has achieved a significant technical milestone in the South West Arkansas project, confirming the engineering design for commercialization [1][3] - The DLE field-pilot plant has successfully surpassed key performance criteria, recovering over 99% of lithium from brine, which is significantly higher than the design target of 95% [4] Project Development - The DLE field-pilot plant operated for three months, processing over 2,385 barrels (100,170 gallons) of brine from the IPC-1 well, completing over 497 DLE cycles [4] - The project has processed a total of 28,367,185 gallons of brine and completed 11,206 cycles of DLE at the Demonstration Plant since 2020 [4] Product Qualification - Large volumes of concentrated and purified DLE product have been sent to third-party vendors for conversion into battery-quality lithium carbonate, which will be used in the qualification process with potential off-take partners [1][4] - Approximately 970 gallons (3,672 liters) of a 6% lithium chloride solution has been produced, with expectations of generating around 27 kg of battery-quality lithium carbonate by May 2025 [4] Technology and Operations - The DLE technology utilized in the field-pilot plant is based on KTS Li-ProTM Lithium Selective Sorption technology, which has been instrumental in optimizing the extraction process [4] - Standard Lithium has been operating a large-scale Demonstration Plant in Arkansas for five years, processing over 28 million gallons of Smackover brine, which has been crucial for developing and streamlining the extraction flowsheet [3]

Core Insights - Standard Lithium Ltd. is a leading near-commercial lithium developer focused on sustainable lithium production [2] - The company will participate in the 37th Annual Roth Conference from March 16 to 18, 2025, in Dana Point, California [1] Company Overview - Standard Lithium is dedicated to the sustainable development of high-grade lithium-brine properties in the United States [2] - The company prioritizes projects with high-quality resources, robust infrastructure, skilled labor, and streamlined permitting [2] - Its flagship projects are located in the Smackover Formation in Arkansas and Texas, with a focus on commercial-scale lithium production using Direct Lithium Extraction (DLE) [2] - Standard Lithium is advancing the South West Arkansas project in partnership with Equinor and the Phase 1A project with LANXESS Corporation [2] - The company also holds interests in mineral leases in the Mojave Desert, California [2] Event Participation - Senior leadership, including the CFO and Director of Finance, will host one-on-one meetings during the Roth Conference [1] - Interested investors can contact Standard Lithium's Investor Relations for more information [1]

Financial Performance - Net revenue for the three months ended January 31, 2025, was $1,681 million, representing a 1% increase compared to the same period last year[131]. - Net income for the three months ended January 31, 2025, was $318 million, down from $348 million in the same period last year[133]. - Cash provided by operations was $431 million for the three months ended January 31, 2025, compared to $485 million in the same period last year[133]. - Total net revenue for the three months ended January 31, 2025, was $1,681 million, representing a 1% increase compared to $1,658 million in the same period last year[150]. - Income from operations for the three months ended January 31, 2025, decreased by $8 million or 2% to $376 million, despite a revenue increase of $23 million[158]. - Income from operations for the three months ended January 31, 2025, increased by $3 million or 3% on a corresponding revenue increase of $27 million[177]. Revenue Segmentation - Revenue from the Life Sciences and Diagnostics Markets segment increased by 4% year-over-year, while the Applied Markets segment saw a decrease of 4%[131]. - Revenue in the Life Sciences and Diagnostics Markets segment increased by 4% to $647 million, while the Agilent CrossLab segment saw a 1% increase to $696 million; however, the Applied Markets segment experienced a 4% decline to $338 million[150][151][152]. - Revenue in the Americas increased by 10%, while Europe saw a 3% increase; however, revenue in Asia Pacific decreased by 5%[169]. - Services and other revenue increased by 7% year-over-year, driven by strong growth in contract repair and preventative maintenance services[149]. Cost and Expenses - The total gross margin for the three months ended January 31, 2025, decreased by 1 percentage point to 53.5% compared to 54.8% in the same period last year[153][154]. - Research and development expenses decreased by 12% to $113 million, while selling, general and administrative expenses increased by 3% to $410 million[153][155][156]. - Research and development expenses decreased by 7% to $26 million for the three months ended January 31, 2025, primarily due to lower salary expenses[185]. - Selling, general and administrative expenses increased by 3% to $143 million for the three months ended January 31, 2025, due to higher corporate infrastructure expenses[186]. - Operating margin for the three months ended January 31, 2025, decreased to 31.8%, down 1 percentage point from 32.4% in the same period last year[184]. Shareholder Returns - The company paid cash dividends of $0.248 per common share, totaling $71 million, during the three months ended January 31, 2025[134]. - The 2023 share repurchase program authorized the purchase of up to $2.0 billion of common stock, with $90 million spent to repurchase 649,857 shares in the three months ended January 31, 2025[136]. - The company repurchased and retired 649,857 shares for $90 million under the 2023 repurchase program during the three months ended January 31, 2025, with remaining authorization to repurchase approximately $284 million[206]. - Cash dividends paid during the three months ended January 31, 2025, were $0.248 per common share, totaling approximately $71 million, compared to $0.236 per share or $69 million in the same period of 2024[208]. Cash Flow and Investments - Net cash provided by operating activities was $431 million for the three months ended January 31, 2025, compared to $485 million for the same period in 2024[200]. - Net cash used in investing activities was $94 million for the three months ended January 31, 2025, compared to $95 million in the same period of 2024[203]. - Investments in property, plant and equipment were $97 million for the three months ended January 31, 2025, compared to $90 million in the same period of 2024, with total capital expenditures expected to be approximately $450 million for the current year[204]. - Net cash used in financing activities for the three months ended January 31, 2025, was $180 million, a decrease from $240 million in the same period of 2024[205]. Market Outlook and Strategy - The company anticipates a steady recovery in customer capital budgets and remains optimistic about the long-term health of key end markets[137]. - The company remains optimistic about long-term growth opportunities, particularly in the life sciences and diagnostics markets, and plans to continue investing in research and development[171]. - Restructuring plans are expected to result in approximately $100 million in annual cost savings across all business segments[141]. - The organizational structure was changed in November 2024 to support a market-focused strategy, resulting in a new segmentation of business units[165]. Foreign Currency Impact - Foreign currency movements negatively impacted revenue growth by 2 percentage points for the three months ended January 31, 2025[146]. - Approximately 47% of revenue was generated in U.S. dollars during the three months ended January 31, 2025, with an unfavorable impact on revenue growth of 2 percentage points due to foreign currency exchange rate changes[220]. - Agilent CrossLab segment revenue increased by 1% year-over-year, with a 2 percentage point unfavorable impact from foreign currency movements[179]. Other Financial Information - Other income for the three months ended January 31, 2025, was $4 million, which included a net gain of $1 million on equity securities[160]. - The effective tax rate for the three months ended January 31, 2025, was 13.4%, with an income tax expense of $49 million, compared to 13.6% and $55 million in the same period last year[162]. - As of January 31, 2025, the company had no borrowings outstanding under its $1.5 billion unsecured credit facility and $750 million incremental revolving credit facility[210]. - Under the U.S. commercial paper program, the company borrowed $301 million and repaid $331 million during the three months ended January 31, 2025, with $10 million outstanding as of January 31, 2025[213]. - The company had commitments for indirect material and services increased by $12 million to $148 million, while commitments to contract manufacturers and suppliers decreased by $38 million to $603 million[217]. - There were no changes in internal control over financial reporting during the quarter ended January 31, 2025, that materially affected the company's internal control[226].

Core Insights - The performance of Agilent Technologies' international operations is crucial for understanding its financial resilience and growth potential [1][2] - The company's reliance on international markets is a key factor in determining its financial success and growth trajectory [2][3] International Revenue Breakdown - Agilent's total revenue for the quarter was $1.68 billion, reflecting a 1.4% increase [4] - Asia Pacific contributed $549 million, accounting for 32.66% of total revenue, which was a surprise of -5.26% compared to the consensus estimate [5] - Europe generated $463 million, making up 27.54% of total revenue, exceeding projections by +3.47% [6] Future Revenue Projections - For the current fiscal quarter, total revenue is anticipated to be $1.63 billion, a 3.5% increase year-over-year, with expected contributions of 33.9% from Asia Pacific and 26.5% from Europe [7] - For the full year, projected total revenue is $6.75 billion, indicating a 3.7% rise from the previous year, with Asia Pacific expected to contribute 34.8% and Europe 26.1% [8] Market Context - The reliance on global markets presents both opportunities and challenges for Agilent, making the analysis of international revenue trends essential for forecasting future performance [9][10] - Analysts are closely monitoring these trends to refine earnings predictions, considering the impact of domestic positioning as well [10]

Core Insights - Agilent Technologies is a leader in life sciences, diagnostics, and applied chemical markets, established through a spin-off from Hewlett-Packard just before 2000 [1] Company Overview - Agilent operates globally with a strong presence in various markets, indicating its significant role in the industry [1]

Financial Data and Key Metrics Changes - The company reported Q1 revenue of $1.681 billion, a 1% increase year-over-year, exceeding expectations [24][36] - Core revenue growth was 1.2%, with an estimated growth of just over 3% when adjusting for Lunar New Year impacts [36] - Gross margin was 54.7%, down from the previous year, primarily due to product mix and currency effects [43][130] - Earnings per share (EPS) for Q1 were $1.31, up 2% from the previous year [45] Business Line Data and Key Metrics Changes - Life Sciences and Diagnostics Markets Group grew 1% to $647 million, driven by high-single-digit growth in LC and LCMS instruments [27][28] - Agilent CrossLab Group reported a 3% increase to $696 million, led by services and positive responses to automation software [29][30] - Applied Markets Group saw a 2% decline to $338 million, attributed to strong China stimulus orders [31] Market Data and Key Metrics Changes - Revenue in the Food market grew 9%, significantly benefiting from China's national stimulus program [38] - Environmental and Forensics market grew 6%, driven by demand for PFAS testing solutions [39] - China revenue declined 4%, but the company captured over 50% of stimulus-related tenders [42][84] Company Strategy and Development Direction - The company is focused on its Ignite Transformation, aiming to enhance customer experience, reduce complexity, and deliver shareholder value [10][11] - Agilent is investing in digital ecosystems and automation to improve lab productivity and customer outcomes [12][16] - The company is committed to innovation and expanding its market leadership, particularly in China [25][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about market recovery, particularly in instrumentation, despite some macroeconomic uncertainties [9][24] - The company is maintaining its core growth guidance of 2.5% to 3.5% for the year, reflecting a prudent approach to potential funding risks [47] - Management noted that NIH funding exposure is limited to around 1% of revenue, and they believe the impact is manageable [33][64] Other Important Information - Agilent's factories in Shanghai and Penang were recognized as Global Lighthouse Networks by the World Economic Forum for advancements in AI and robotics [53][54] - The company was ranked No. 10 on Newsweek's list of America's Most Responsible Companies, highlighting its commitment to sustainability [56] Q&A Session Summary Question: Can you quantify the level of headline risk embedded in the fiscal 2Q guide? - Management acknowledged the prudent guidance due to changes in NIH funding and tariffs but noted increased activity and sentiment from customers, particularly in pharma [62][64] Question: How much of the EPS number in fiscal 2Q is impacted by FX? - The estimated FX impact for the full year is a $0.09 headwind, with a $30 million impact in Q2, translating to a $0.02 to $0.03 impact on EPS [67][68] Question: Can you discuss opportunities within PFAS given the 70% growth? - Demand for PFAS solutions remains strong, with significant growth in environmental, food, and chemical materials markets, driven by new regulations [70][72] Question: What is the impact of the Infinity III launch on growth? - The Infinity III launch has significantly improved win rates and is driving a replacement cycle, particularly among older instruments [76][78] Question: Can you elaborate on the China stimulus impact? - The company won 50% of the stimulus orders, amounting to $35 million, and expects more stimulus in the second half of the year [83][85]

Group 1: Earnings Performance - Agilent Technologies reported quarterly earnings of $1.31 per share, exceeding the Zacks Consensus Estimate of $1.27 per share, and showing an increase from $1.29 per share a year ago, representing an earnings surprise of 3.15% [1] - The company posted revenues of $1.68 billion for the quarter ended January 2025, surpassing the Zacks Consensus Estimate by 0.86%, and showing a slight increase from $1.66 billion year-over-year [2] - Over the last four quarters, Agilent has consistently surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - Agilent shares have declined approximately 0.1% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is $1.33 on revenues of $1.65 billion, and for the current fiscal year, it is $5.56 on revenues of $6.83 billion [7] - The estimate revisions trend for Agilent is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Group 3: Industry Context - The Medical - Products industry, to which Agilent belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Agilent Technologies Q1 FY2025 Financial Results Overview Safe Harbor This presentation contains forward-looking statements (including, without limitation, information, and future guidance on the company's revenue, revenue growth, earnings per share, operating cash flow, capital expenditures, net interest and other/expense, impact of acquisitions and related financing, share repurchases, dividends, diluted share counts, currency exchange rates, and Lunar New Year impact) that involve risks and uncertainties ...